Investigations by Cell-Mediated Immunologic Tests and Therapeutic Trials with Thymopentin in Vaginal Mycoses

Infectious Diseases in Obstetrics and Gynecology

Volumn 4, Issue 4, 1996, Pages 225-231

  Mendling, Werner ^a   Koldovsky, Ursula ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Candida albicans; Candida glabrata; cellular immunity; proliferation tests; vulvovaginitis

Indexed keywords

THYMOPENTIN;

ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; IMMUNE FUNCTION TEST; KILLER CELL; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; VAGINA CANDIDIASIS; VAGINITIS; VULVOVAGINITIS;

EID: 0030484531     PISSN: 10647449     EISSN: 10980997     Source Type: Journal    
DOI: 10.1155/S1064744996000439     Document Type: Article

References (29)

1. Ghannoum MA, Abu-Elteen KH: Pathogenicity determinants of Candida. Mycoses 33:265–282, 1990.
2. Krempl-Lamprecht L: Zur mikrobiologischen Charakteristik von Candida albicans. Int Exp Clin Chemother Suppl 1:16–20, 1990.
3. Mendling W: Die Vaginalcandidose. Dtsch Ges Gynäkol Geburtsh Mitteilungen 4:209–210, 1991.
4. Mendling W: Die Torulopsidose in der Frauenheilkunde. Geburtshilfe Frauenheilkd 44:583–586, 1984.
5. Redondo-Lopez V, Lynch M, Schmidt C, Cook R, Sobel JD: Torulopsis glabrata vaginitis: Clinical aspects and susceptibility to antifungal agents. Obstet Gynecol 76:651–655, 1990.
6. Cohen L: Is more than one application of an antifungal necessary in the treatment of acute vaginal candidosis? Am J Obstet Gynecol 152:961–964, 1985.
7. Sobel JD: Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstet Gynecol 65:435–440, 1985.
8. Mendling W, Koldovsky U: Immunological findings in patients with chronically recurrent vaginal candidosis and new therapeutic approaches. Mycoses 32:386–390, 1989.
9. Mendling W, Metzger P: Bestimmung des sekretorischen Immunglobulin A im Zervikovaginalsekret gesunder Frauen mit einer ELISA-Methode. Geburtschilfe Frauenheilkd 54:417–420, 1994.
10. Mendling W, Koldovsky U: Further immunological investigations in vaginal mycoses. Mycoses 39:177–183, 1996.
11. Koldovsky U, Mendling W: Die proliferative Antwort von Lymphozyten Candidaerkrankter auf Stimulation mit verschiedenen Candidaantigenen. IV. Intern Workshop Infekt Gyn Geburtsh, München, 1989.
12. Valdimarsson H, Higgs JM, Wells RS, Yamamura M, Hobbs JR, Holt L: Immune abnormalities associated with chronic mucocutaneus candidiasis. Cell Immun 6:348–361, 1973.
13. Fegeler K, Macher E, Nolting S: Tierexperimentelle Untersuchungen zur Immunität bei Infekten mit Candida albicans. Mykosen 21:127–137, 177–189, 201–222, 1978.
14. Meinhof W: Candida—Mykosen und cellulare Immundefekte. Z Haut Geschlechtskr 141:1–10, 1979.
15. Coegniet E, Kühnast R: Rezidivierende Candidiasis. Adjuvante Chemotherapie mit verschiedenen Echinacin-Darreichungsformen. Therapiewoche 36:3352–3358, 1986.
16. Török J, Farkas B: Die Bedeutung der Phagozyten und des T-Lymphozyten-Systems bei der Abwehr von Candida albicans—Infektionen (Übersicht). Mykosen 29: 486–490, 1986.
17. Dwajari D, Simon M, Burkert B: Macrophage functions in patients suffering from chronic mucocutaneous candidiasis. Arch Dermatol Res 275:412–416, 1983.
18. Witkin SS, Hirsch J, Ledger WJ: A macrophage defect in women with recurrent Candida vaginitis and its reversal in vitro by prostaglandin inhibitors. Am J Obstet Gynecol 155:790–795, 1986.
19. Sinha BK, Monga DP, Prasad S: Studies on the role of macrophages in experimental candidosis in mice. Mykosen 30:105–112, 1987.
20. Greenfield RA: Host defense system interactions with Candida. J Med Veter Mycol 30:89–104, 1992.
21. Vecchiarelli A, Bistoni F, Cenci E, Perito S, Cassone A: In vitro killing of Candida species by murine immunoeffectors and its relationship to the experimental pathogenicity. Sabouraudia (J Med Veter Mycol) 23:377–387, 1985.
22. Hauck H, Simon B, Geschwender B, Djawari D: Beeinflußbarkeit von Phagozytose und intrazellulärer Abtötung von Candida albicans durch PMNL durch Stammeigenschaften des Erregers. Z Haut Geschlechtskr 150:660–666, 1985.
23. Walther T, Rytter M, Schönborn C, Haustein UF: Differences in the intracellular killing of proteinase-positive and proteinase-negative Candida albicans strains by granulocytes. Mykosen 29:159–161, 1986.
24. Piccolella E, Lombardi G, Morelli R: Human lymphocyte activating properties of a purified polysaccharide from Candida albicans: B- and T-cell cooperation in the mitogenic response. J Immunol 125:2082–2088, 1980.
25. Melbye M, Schonheyder H, Kestens L, Stenderup A, Gigase PL, Ebbesen P, Biggar RJ: Carrige of oral Candida albicans associated with high number of circulating suppressor-T-lymphocytes. J Infect Dis 152:1356–1357, 1985.
26. Danley DJ, Polakoff J: Rapid killing of monocytes in vitro by Candida albicans yeast cells. Infect Immun 51:307–313, 1986.
27. Domer JE, Garner RE: Immunomodulation in response to Candida. In Kustak E (ed): Immunology of Fungal Diseases. New York: Marcel Dekker, Inc., 1989.
28. Mathur S, Mathur RS, Dowda H, Williamson O, Faulk WP, Fudenberg HH: Sex steroid hormones and antibodies to Candida albicans. Clin Exp Immunol 33:79–87, 1978.
29. Witkin SS, Yu R, Ledger WJ: Inhibition of Candida induced lymphocyte proliferation by lymphocytes and sera from women with recurrent vaginitis. Am J Obstet Gynecol 147:809–811, 1983.